Back to Journals » OncoTargets and Therapy » Volume 9

miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway

Authors Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong J, Feng J

Received 20 April 2016

Accepted for publication 3 August 2016

Published 3 October 2016 Volume 2016:9 Pages 6009—6019

DOI https://doi.org/10.2147/OTT.S110923

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Chiung-Kuei Huang

Peer reviewer comments 4

Editor who approved publication: Dr William Cho


Bo Shen,* Shaorong Yu,* Yan Zhang, Yuan Yuan, Xiaoyou Li, Jian Zhong, Jifeng Feng

Department of Oncology, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Background: The aim of this study was to determine the role of miRNA-590-5p in gastric cancer (GC) progression. 
Methods: Quantitative real-time polymerase chain reaction was performed to measure endogenous miR-590-5p levels in GC cells and tissues. Overexpression or knockdown of miR-590-5p in GC cells was performed by transfection with mimics or an inhibitor, respectively. MTT, matrigel transwell, and Western blot assays were used to assess the effects of miR-590-5p on cell proliferation, invasion, chemosensitivity of GC cells, and the AKT pathway, respectively. In silico prediction and luciferase reporter activity were used to identify potential targets of miR-590-5p. A xenograft model was also established to evaluate the function of miR-590-5p in vivo. 
Results: The expression of miR-590-5p was significantly increased in GC cells and tissues, and upregulated miR-590-5p was associated with increased tumor size, lymph node metastasis, and poor survival. Overexpression of miR-590-5p promoted cell proliferation and invasion and reduced the sensitivity of GC cells to cisplatin and paclitaxel. In contrast, inhibition of miR-590-5p had the opposite effects on GC cells. RECK was identified as a direct target of miR-590-5p. Knockdown of RECK accelerated cell proliferation and motility and decreased the drug sensitivity. Furthermore, reintroduction of RECK inhibited the oncogenic effects of miR-590-5p by suppressing cell proliferation and invasion and increasing drug sensitivity. We found that the AKT/ERK and STAT3 signaling pathways were activated by miR-590-5p overexpression. The chemoresistance of miR-590-5p was also verified by in vivo analysis. 
Conclusion: In summary, we suggest that the miR-590-5p/RECK/AKT axis contributes to GC and may serve as a promising therapeutic target for treatment.

Keywords: miR-590, RECK, invasion, prognosis, AKT pathway, gastric cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]